Neuroblastoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Neuroblastoma – Pipeline Review, H2 2016’, provides an overview of the Neuroblastoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Neuroblastoma

The report reviews pipeline therapeutics for Neuroblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Neuroblastoma therapeutics and enlists all their major and minor projects

The report assesses Neuroblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Neuroblastoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neuroblastoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ability Pharmaceuticals SL

Acetylon Pharmaceuticals Inc

Advanced Accelerator Applications SA

Alissa Pharma

Ampio Pharmaceuticals Inc

APEIRON Biologics AG

AstraZeneca Plc

Bayer AG

Bellicum Pharmaceuticals Inc

Bexion Pharmaceuticals LLC

BioLineRx Ltd

Bionucleon Srl

Biotec Pharmacon ASA

Cancer Prevention Pharmaceuticals, Inc.

Cebiotex SL

Celgene Corp

Cielo Therapeutics Inc

Cleveland BioLabs Inc

Codagenix, Inc.

CorMedix Inc

Curis Inc

Cyclacel Pharmaceuticals Inc

DEKK-TEC Inc

EnGeneIC Ltd

Errant Gene Therapeutics LLC

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Green Cross Cell Corp

Ignyta Inc

Incuron, LLC

Juno Therapeutics Inc

Kolltan Pharmaceuticals Inc

Lindis Biotech GmbH

MabVax Therapeutics Holdings Inc

MediaPharma srl

Merck & Co Inc

Merrimack Pharmaceuticals Inc

Morphogenesis Inc

Novartis AG

Novogen Ltd

OGD2 Pharma SAS

Pfizer Inc

Pharmacyclics Inc

Progenics Pharmaceuticals Inc

ProNAi Therapeutics Inc

Recombio SL

Ribomic Inc.

Sapience Therapeutics Inc

Sareum Holdings Plc

Shionogi & Co Ltd

Syros Pharmaceuticals Inc

Tiltan Pharma Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Neuroblastoma Overview 6

Therapeutics Development 7

Neuroblastoma - Therapeutics under Development by Companies 9

Neuroblastoma - Therapeutics under Investigation by Universities/Institutes 13

Neuroblastoma - Pipeline Products Glance 15

Neuroblastoma - Products under Development by Companies 18

Neuroblastoma - Products under Investigation by Universities/Institutes 23

Neuroblastoma - Companies Involved in Therapeutics Development 25

Neuroblastoma - Therapeutics Assessment 77

Drug Profiles 95

Neuroblastoma - Dormant Projects 338

Neuroblastoma - Discontinued Products 342

Neuroblastoma - Product Development Milestones 343

Appendix 353

List of Tables

List of Tables

Number of Products under Development for Neuroblastoma, H2 2016 19

Number of Products under Development for Neuroblastoma – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Development by Companies, H2 2016 (Contd..1) 22

Number of Products under Development by Companies, H2 2016 (Contd..2) 23

Number of Products under Development by Companies, H2 2016 (Contd..3) 24

Number of Products under Investigation by Universities/Institutes, H2 2016 26

Comparative Analysis by Late Stage Development, H2 2016 27

Comparative Analysis by Clinical Stage Development, H2 2016 28

Comparative Analysis by Early Stage Development, H2 2016 29

Products under Development by Companies, H2 2016 30

Products under Development by Companies, H2 2016 (Contd..1) 31

Products under Development by Companies, H2 2016 (Contd..2) 32

Products under Development by Companies, H2 2016 (Contd..3) 33

Products under Development by Companies, H2 2016 (Contd..4) 34

Products under Investigation by Universities/Institutes, H2 2016 35

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 36

Neuroblastoma – Pipeline by Ability Pharmaceuticals SL, H2 2016 37

Neuroblastoma – Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 38

Neuroblastoma – Pipeline by Advanced Accelerator Applications SA, H2 2016 39

Neuroblastoma – Pipeline by Alissa Pharma, H2 2016 40

Neuroblastoma – Pipeline by Ampio Pharmaceuticals Inc, H2 2016 41

Neuroblastoma – Pipeline by APEIRON Biologics AG, H2 2016 42

Neuroblastoma – Pipeline by AstraZeneca Plc, H2 2016 43

Neuroblastoma – Pipeline by Bayer AG, H2 2016 44

Neuroblastoma – Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 45

Neuroblastoma – Pipeline by Bexion Pharmaceuticals LLC, H2 2016 46

Neuroblastoma – Pipeline by BioLineRx Ltd, H2 2016 47

Neuroblastoma – Pipeline by Bionucleon Srl, H2 2016 48

Neuroblastoma – Pipeline by Biotec Pharmacon ASA, H2 2016 49

Neuroblastoma – Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016 50

Neuroblastoma – Pipeline by Cebiotex SL, H2 2016 51

Neuroblastoma – Pipeline by Celgene Corp, H2 2016 52

Neuroblastoma – Pipeline by Cielo Therapeutics Inc, H2 2016 53

Neuroblastoma – Pipeline by Cleveland BioLabs Inc, H2 2016 54

Neuroblastoma – Pipeline by Codagenix, Inc., H2 2016 55

Neuroblastoma – Pipeline by CorMedix Inc, H2 2016 56

Neuroblastoma – Pipeline by Curis Inc, H2 2016 57

Neuroblastoma – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 58

Neuroblastoma – Pipeline by DEKK-TEC Inc, H2 2016 59

Neuroblastoma – Pipeline by EnGeneIC Ltd, H2 2016 60

Neuroblastoma – Pipeline by Errant Gene Therapeutics LLC, H2 2016 61

Neuroblastoma – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 62

Neuroblastoma – Pipeline by GlaxoSmithKline Plc, H2 2016 63

Neuroblastoma – Pipeline by Green Cross Cell Corp, H2 2016 64

Neuroblastoma – Pipeline by Ignyta Inc, H2 2016 65

Neuroblastoma – Pipeline by Incuron, LLC, H2 2016 66

Neuroblastoma – Pipeline by Juno Therapeutics Inc, H2 2016 67

Neuroblastoma – Pipeline by Kolltan Pharmaceuticals Inc, H2 2016 68

Neuroblastoma – Pipeline by Lindis Biotech GmbH, H2 2016 69

Neuroblastoma – Pipeline by MabVax Therapeutics Holdings Inc, H2 2016 70

Neuroblastoma – Pipeline by MediaPharma srl, H2 2016 71

Neuroblastoma – Pipeline by Merck & Co Inc, H2 2016 72

Neuroblastoma – Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 73

Neuroblastoma – Pipeline by Morphogenesis Inc, H2 2016 74

Neuroblastoma – Pipeline by Novartis AG, H2 2016 75

Neuroblastoma – Pipeline by Novogen Ltd, H2 2016 76

Neuroblastoma – Pipeline by OGD2 Pharma SAS, H2 2016 77

Neuroblastoma – Pipeline by Pfizer Inc, H2 2016 78

Neuroblastoma – Pipeline by Pharmacyclics Inc, H2 2016 79

Neuroblastoma – Pipeline by Progenics Pharmaceuticals Inc, H2 2016 80

Neuroblastoma – Pipeline by ProNAi Therapeutics Inc, H2 2016 81

Neuroblastoma – Pipeline by Recombio SL, H2 2016 82

Neuroblastoma – Pipeline by Ribomic Inc., H2 2016 83

Neuroblastoma – Pipeline by Sapience Therapeutics Inc, H2 2016 84

Neuroblastoma – Pipeline by Sareum Holdings Plc, H2 2016 85

Neuroblastoma – Pipeline by Shionogi & Co Ltd, H2 2016 86

Neuroblastoma – Pipeline by Syros Pharmaceuticals Inc, H2 2016 87

Neuroblastoma – Pipeline by Tiltan Pharma Ltd, H2 2016 88

Assessment by Monotherapy Products, H2 2016 89

Assessment by Combination Products, H2 2016 90

Number of Products by Stage and Target, H2 2016 92

Number of Products by Stage and Mechanism of Action, H2 2016 98

Number of Products by Stage and Route of Administration, H2 2016 104

Number of Products by Stage and Molecule Type, H2 2016 106

Neuroblastoma – Dormant Projects, H2 2016 350

Neuroblastoma – Dormant Projects (Contd..1), H2 2016 351

Neuroblastoma – Dormant Projects (Contd..2), H2 2016 352

Neuroblastoma – Dormant Projects (Contd..3), H2 2016 353

Neuroblastoma – Discontinued Products, H2 2016 354

List of Figures

List of Figures

Number of Products under Development for Neuroblastoma, H2 2016 19

Number of Products under Development for Neuroblastoma – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Investigation by Universities/Institutes, H2 2016 25

Comparative Analysis by Late Stage Development, H2 2016 27

Comparative Analysis by Clinical Stage Development, H2 2016 28

Comparative Analysis by Early Stage Products, H2 2016 29

Assessment by Monotherapy Products, H2 2016 89

Number of Products by Top 10 Targets, H2 2016 91

Number of Products by Stage and Top 10 Targets, H2 2016 91

Number of Products by Top 10 Mechanism of Actions, H2 2016 97

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 97

Number of Products by Top 10 Routes of Administration, H2 2016 103

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 103

Number of Products by Top 10 Molecule Types, H2 2016 105

Number of Products by Stage and Top 10 Molecule Types, H2 2016 105

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports